Market Closed -
Nasdaq
04:00:00 2024-06-06 pm EDT
|
5-day change
|
1st Jan Change
|
11.02
USD
|
-1.34%
|
|
+9.65%
|
-51.45%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
335.8
|
300.2
|
107.4
|
269.6
|
972.7
|
539.2
|
-
|
-
|
Enterprise Value (EV)
1 |
199.6
|
191.6
|
-14.85
|
163
|
731.4
|
284.8
|
366.1
|
297.3
|
P/E ratio
|
-3.43
x
|
-8.67
x
|
-2.11
x
|
-5.11
x
|
-13.8
x
|
-5.28
x
|
-5.01
x
|
-4.94
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
86.3
x
|
252
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
58.6
x
|
139
x
|
EV / EBITDA
|
-10.7
x
|
-5.72
x
|
0.33
x
|
-3.06
x
|
-9.99
x
|
-2.65
x
|
-3.06
x
|
-2.2
x
|
EV / FCF
|
-11.9
x
|
-6.99
x
|
0.42
x
|
-3.34
x
|
-13.5
x
|
-2.77
x
|
-4.03
x
|
-2.47
x
|
FCF Yield
|
-8.39%
|
-14.3%
|
238%
|
-30%
|
-7.42%
|
-36.2%
|
-24.8%
|
-40.4%
|
Price to Book
|
2.43
x
|
2.74
x
|
0.93
x
|
2.6
x
|
4.6
x
|
2.74
x
|
4.42
x
|
2.85
x
|
Nbr of stocks (in thousands)
|
24,034
|
24,055
|
28,332
|
29,141
|
42,849
|
48,277
|
-
|
-
|
Reference price
2 |
13.97
|
12.48
|
3.790
|
9.250
|
22.70
|
11.17
|
11.17
|
11.17
|
Announcement Date
|
3/30/20
|
3/16/21
|
3/17/22
|
3/16/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
6.25
|
2.143
|
EBITDA
1 |
-18.58
|
-33.48
|
-45.52
|
-53.18
|
-73.23
|
-107.3
|
-119.7
|
-134.9
|
EBIT
1 |
-18.68
|
-33.83
|
-46.31
|
-54.14
|
-74.66
|
-116
|
-128.3
|
-154.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,052.48%
|
-7,194.16%
|
Earnings before Tax (EBT)
1 |
-16.94
|
-33.34
|
-46.29
|
-52.98
|
-67.68
|
-108.3
|
-122.4
|
-148.4
|
Net income
1 |
-22.27
|
-33.34
|
-46.29
|
-52.98
|
-67.68
|
-108.3
|
-122.4
|
-148.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,957.86%
|
-6,924.81%
|
EPS
2 |
-4.070
|
-1.440
|
-1.800
|
-1.810
|
-1.650
|
-2.115
|
-2.229
|
-2.262
|
Free Cash Flow
1 |
-16.74
|
-27.4
|
-35.28
|
-48.83
|
-54.24
|
-103
|
-90.8
|
-120.2
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,452.8%
|
-5,609.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/20
|
3/16/21
|
3/17/22
|
3/16/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-22.81
|
-27.64
|
-28.43
|
-29.26
|
-30.11
|
-
|
-
|
EBIT
1 |
-13.89
|
-13
|
-13.06
|
-11.78
|
-16.3
|
-16.96
|
-15.89
|
-18.67
|
-23.15
|
-28.03
|
-29.3
|
-30.87
|
-32.25
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-13.89
|
-12.95
|
-12.91
|
-11.43
|
-15.69
|
-15.85
|
-14.49
|
-16.45
|
-20.89
|
-25.05
|
-27.46
|
-29.18
|
-30.57
|
-
|
-
|
Net income
1 |
-13.89
|
-12.95
|
-12.91
|
-11.43
|
-15.69
|
-15.85
|
-14.49
|
-16.45
|
-20.89
|
-25.05
|
-27.46
|
-29.18
|
-30.56
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4900
|
-0.4500
|
-0.4500
|
-0.3900
|
-0.5200
|
-0.4500
|
-0.3700
|
-0.3700
|
-0.4600
|
-0.5100
|
-0.5448
|
-0.5406
|
-0.5395
|
-0.6150
|
-0.6350
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/16/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/21/24
|
5/15/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
136
|
109
|
122
|
107
|
241
|
254
|
173
|
242
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-16.7
|
-27.4
|
-35.3
|
-48.8
|
-54.2
|
-103
|
-90.8
|
-120
|
ROE (net income / shareholders' equity)
|
-26.6%
|
-26.9%
|
-40.7%
|
-47.6%
|
-39.7%
|
-51.8%
|
-64.1%
|
-63.5%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
5.760
|
4.550
|
4.080
|
3.560
|
4.940
|
4.070
|
2.530
|
3.920
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.69
|
0.64
|
1.17
|
2.45
|
0.69
|
1.4
|
5
|
10
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
80%
|
466.67%
|
Announcement Date
|
3/30/20
|
3/16/21
|
3/17/22
|
3/16/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
11.02
USD Average target price
33.56
USD Spread / Average Target +204.50% Consensus |
1st Jan change
|
Capi.
|
---|
| -51.45% | 539M | | +19.33% | 125B | | +13.95% | 109B | | -3.53% | 24.74B | | +2.71% | 22.67B | | -9.95% | 18.14B | | -41.48% | 16.67B | | -12.62% | 16.64B | | +0.99% | 13.45B | | +21.79% | 11.32B |
Bio Therapeutic Drugs
|